UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/14.01.26 | Real-time BOERSE MUENCHEN 11:42:05 2024-06-27 am EDT | ||
| 2.05 EUR | 0.00% |
|
| Current month | +13.89% | ||
| 1 month | +13.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 2.05 | 0.00% |
| 24-06-26 | 2.05 | +3.54% |
| 24-06-25 | 1.98 | -1.49% |
| 24-06-24 | 2.01 | +4.69% |
| 24-06-21 | 1.92 | -1.54% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 11:42 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD2910 |
| ISIN | DE000HD29104 |
| Date issued | 2024-01-29 |
| Strike | 700 $ |
| Maturity | 2026-01-14 (566 Days) |
| Parity | 10 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.54 € |
|---|---|
| Lowest since issue | 0.77 € |
| Spread | 0.04 € |
| Spread % | 1.94% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Warrants
- Warrant
